DKIP SSO

How does oral semaglutide compare to a DPP-4 inhibitor? Find our in our next journal club

Join Professor Melanie Davies as she helps answer this question and covers topics including:

Suitability of oral formulations for patients
A comparison of oral semaglutide with DDP-4 inhibitor sitagliptin
Other phase three trials assessing different comparators

During Professor Davies’ talk, you can write in with your own questions and queries, which will be answered live at the end of the session. Be sure to join our next journal club and have all your questions answered!

One-time registration provides access to all free CME activities and content.

Email address

Password

Confirm password

Specialty

Country

Privacy

We take your privacy seriously, please click here to view our Privacy Notice. The information above is required to help us ensure our free CME activities and learning content is suitable for your needs.

Please state that you have read and agreed to these Terms of Use before completing registration.

I agree to the Terms of Use

Let us know how you'd like to be contacted

As part of our service, we will send you a small number of emails to request a follow-up to your Commitment to Change.

Please let us know if you would like to be contacted for any of the following:

I consent to be contacted by email in relation to activities and learning available on this website for example to notify you when new content is launched.

I consent to be contacted by email in relation to information and events relating to Diabetes both in the UK and abroad and in the area of my Specialty.

You can notify us of any changes to your preferences or registration information by emailing contact@knowledgeinpractice.eu.

"We", includes Liberum Independent Medical Education Limited "Liberum" (Data Controller) and Open Health Communications LLP (Data Processor).

For further details on how your data is used and stored please read this Privacy Policy

GLP-1 Receptor Agonists

Comprehensive guidance on the role of GLP-1 RAs in type 2 diabetes care

In the new era of individualised diabetes care, where do GLP-1 receptor agonists (RAs) fit? These interactive modules summarise international recommendations, including clinical decision-making and addressing adverse events. Now featuring interactive case study clinics and digital symposia, a new way to learn both alone and with colleagues.

Insulin eLearning

Cutting-edge education on insulin therapy and patient support techniques

This educational programme is designed to summarise global guidance across all levels of diabetes care. From fundamental pathophysiology to addressing post-prandial glucose, these e-learning modules will allow you to both consolidate existing knowledge and discover global guidance in managing type 1 and type 2 diabetes.

Diabetes Knowledge in Practice

How does oral semaglutide compare to a DPP-4 inhibitor? Find our in our next journal club

Privacy

Let us know how you'd like to be contacted

Recover password

Diabetes Knowledge in Practice

How does oral semaglutide compare to a DPP-4 inhibitor? Find our in our next journal club

Privacy

Let us know how you'd like to be contacted

Recover password

CME-in-a-box

Design your own interactive meetings using a bank of CME-accredited resources

GLP-1 Receptor Agonists

Comprehensive guidance on the role of GLP-1 RAs in type 2 diabetes care

Expert panel discussions

Global guidance and novel data direct from major congresses

Insulin eLearning

Cutting-edge education on insulin therapy and patient support techniques

Journal clubs

Regular interactive discussions with leading experts on recent publications